Importantly, peroxidasin has been reported to be highly expressed in fibrotic contexts, including in murine models of kidney fibrosis and non-alcoholic fatty liver disease [116–118]. Here, PXDN is linked to metabolic dysfunction-associated steatotic liver disease.